Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases

Nicholas Schrader; JC DUIPMANS; Bouwe Molenbuur; André Wolff; Marcel F. Jonkman

doi:10.1111/bjd.17341

Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases

Nicholas Schrader^*, JC DUIPMANS, Bouwe Molenbuur, André Wolff, Marcel F. Jonkman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

24 Citations (Scopus)

323 Downloads (Pure)

Abstract

Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain-care in EB however are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been increasingly studied for pain conditions of various etiologies and pose as a novel dimension for pain-care in EB. We present three cases of EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol (THC) and cannabidiol (CBD). All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake. This article is protected by copyright. All rights reserved

Original language	English
Pages (from-to)	922-924
Number of pages	3
Journal	BRITISH JOURNAL OF DERMATOLOGY
Volume	180
Issue number	4
DOIs	https://doi.org/10.1111/bjd.17341
Publication status	Published - Apr-2019

Access to Document

10.1111/bjd.17341Licence: CC BY-NC-ND

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa a report of three casesFinal publisher's version, 107 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{704d04f5585741b6805e36204f37dc14,

title = "Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases",

abstract = "Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain-care in EB however are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been increasingly studied for pain conditions of various etiologies and pose as a novel dimension for pain-care in EB. We present three cases of EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol (THC) and cannabidiol (CBD). All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake. This article is protected by copyright. All rights reserved",

author = "Nicholas Schrader and JC DUIPMANS and Bouwe Molenbuur and Andr{\'e} Wolff and Jonkman, {Marcel F.}",

year = "2019",

month = apr,

doi = "10.1111/bjd.17341",

language = "English",

volume = "180",

pages = "922--924",

journal = "BRITISH JOURNAL OF DERMATOLOGY",

issn = "0007-0963",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases

AU - Schrader, Nicholas

AU - DUIPMANS, JC

AU - Molenbuur, Bouwe

AU - Wolff, André

AU - Jonkman, Marcel F.

PY - 2019/4

Y1 - 2019/4

N2 - Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain-care in EB however are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been increasingly studied for pain conditions of various etiologies and pose as a novel dimension for pain-care in EB. We present three cases of EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol (THC) and cannabidiol (CBD). All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake. This article is protected by copyright. All rights reserved

AB - Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain-care in EB however are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been increasingly studied for pain conditions of various etiologies and pose as a novel dimension for pain-care in EB. We present three cases of EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol (THC) and cannabidiol (CBD). All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake. This article is protected by copyright. All rights reserved

U2 - 10.1111/bjd.17341

DO - 10.1111/bjd.17341

M3 - Article

SN - 0007-0963

VL - 180

SP - 922

EP - 924

JO - BRITISH JOURNAL OF DERMATOLOGY

JF - BRITISH JOURNAL OF DERMATOLOGY

IS - 4

ER -